Galmed Pharmaceuticals (NASDAQ:GLMD) Coverage Initiated by Analysts at StockNews.com

Research analysts at StockNews.com initiated coverage on shares of Galmed Pharmaceuticals (NASDAQ:GLMDGet Free Report) in a research note issued to investors on Thursday. The firm set a “sell” rating on the biopharmaceutical company’s stock.

Separately, Maxim Group raised shares of Galmed Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Monday, July 24th.

Get Our Latest Report on GLMD

Galmed Pharmaceuticals Trading Down 2.4 %

Galmed Pharmaceuticals stock opened at $0.40 on Thursday. The firm has a market capitalization of $672,000.00, a PE ratio of -0.06 and a beta of 0.95. Galmed Pharmaceuticals has a 12-month low of $0.35 and a 12-month high of $14.18. The firm has a 50-day moving average price of $0.52 and a 200-day moving average price of $1.99.

Institutional Trading of Galmed Pharmaceuticals

A number of institutional investors have recently bought and sold shares of the stock. Millennium Management LLC increased its holdings in shares of Galmed Pharmaceuticals by 218.4% during the 4th quarter. Millennium Management LLC now owns 149,217 shares of the biopharmaceutical company’s stock valued at $75,000 after purchasing an additional 102,351 shares in the last quarter. Cambridge Investment Research Advisors Inc. acquired a new position in shares of Galmed Pharmaceuticals during the 1st quarter valued at about $42,000. Finally, Raymond James Financial Services Advisors Inc. boosted its position in shares of Galmed Pharmaceuticals by 158.9% during the 1st quarter. Raymond James Financial Services Advisors Inc. now owns 63,310 shares of the biopharmaceutical company’s stock valued at $101,000 after acquiring an additional 38,856 shares during the last quarter. 20.89% of the stock is currently owned by institutional investors and hedge funds.

About Galmed Pharmaceuticals

(Get Free Report)

Galmed Pharmaceuticals Ltd., a biopharmaceutical company, focuses on the development of therapeutics for the treatment of liver diseases. It develops Aramchol, an oral therapy, which is in Phase III study for the treatment of non-alcoholic steato-hepatitis (NASH) in patients with overweight or obesity and who are pre-diabetic or type-II-diabetes mellitus.

Read More

Receive News & Ratings for Galmed Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Galmed Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.